fbpx Skip to main content

Member's Profile

Immix Biopharma Inc.

11400 Olympic Blvd, Ste 200
Los Angeles,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2016
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Immix Biopharma Inc.
Biotech Company
ImmixBio™ is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. In addition to oncology, our pipeline includes Tissue-Specific Biologic™ candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Learn more at www.immixbio.com.
Related News
No related news posted by this Member